<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02938923</url>
  </required_header>
  <id_info>
    <org_study_id>R01AG051647</org_study_id>
    <secondary_id>201609077</secondary_id>
    <nct_id>NCT02938923</nct_id>
  </id_info>
  <brief_title>Starting a Testosterone and Exercise Program After Hip Injury</brief_title>
  <acronym>STEP-HI</acronym>
  <official_title>Combining Testosterone Therapy and Exercise to Improve Function Post Hip Fracture</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The University of Texas Medical Branch, Galveston</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Harvard University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Connecticut</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pittsburgh Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized controlled double-blinded multi-center clinical trial enrolling&#xD;
      female hip fracture patients who are 65 and older. It will compare the effects of six months&#xD;
      of supervised exercise training combined with daily topical testosterone gel, to six months&#xD;
      of supervised exercise and inactive gel, and to Enhanced Usual Care. Out of nine&#xD;
      participants, 4 will receive topical testosterone gel and a supervised exercise training&#xD;
      program; 4 will receive topical inactive gel and a supervised exercise training program; and&#xD;
      1 will receive a home exercise program. All participants will receive nutritional counseling,&#xD;
      and calcium and vitamin D supplements.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hip fractures are common among older women and can have a devastating impact on their ability&#xD;
      to remain independent. A clinically important functional decline and failure to recover&#xD;
      following a hip fracture has been documented as late as a year after the fracture, even among&#xD;
      women who were functioning at high levels before the event. Age-associated androgen&#xD;
      deficiency in women contributes to deficits in muscle mass, strength and power that are&#xD;
      common in this patient population before the fracture, and are exacerbated afterward. A pilot&#xD;
      study of testosterone (T) supplementation in elderly female hip fracture patients has&#xD;
      demonstrated the feasibility of T treatment in this population, and showed gains in lean body&#xD;
      mass (LBM) and muscle strength with active drug, compared to placebo. The benefits of&#xD;
      exercise in restoring muscle strength and physical function after a hip fracture have been&#xD;
      documented. However, it remains unclear whether T treatment can augment the effects of&#xD;
      exercise on mobility and patient-reported function after hip fracture.&#xD;
&#xD;
      The STEP-HI study is a 3-group, multi-center, randomized, placebo-controlled, double-blinded,&#xD;
      parallel group clinical trial in older female hip fracture patients. 168 female hip fracture&#xD;
      patients, age 65 years and older, will be enrolled from multiple clinical sites, using&#xD;
      objective screening criteria for T deficiency (serum total testosterone level &lt; 60 ng/dL) and&#xD;
      physical frailty (Modified Physical Performance Test (PPT) Score of 12-28). The trial will&#xD;
      compare the effects of Enhanced Usual Care with home exercises and no gel treatment (EUC),&#xD;
      supervised exercise training (EX) with inactive (placebo) gel (EX+P), and EX combined with T&#xD;
      therapy (EX+T), to ascertain the incremental impact of adding T to EX in older adult women&#xD;
      with a recent hip fracture. The study team will carefully monitor testosterone levels,&#xD;
      adverse events, biochemical parameters, and factors related to adherence to the&#xD;
      interventions.&#xD;
&#xD;
      Information from this study has the potential to alter treatment of hip fracture in older&#xD;
      women, a problem that contributes to significant morbidity and mortality, and has a large&#xD;
      public health impact. The STEP-HI study is highly aligned with NIA's mission of identifying&#xD;
      interventions that target common geriatric conditions and improve treatment options for older&#xD;
      adults with multiple morbidities or risk factors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2017</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Participants, investigators, and study staff conducting the interventions will be aware of the exercise group assignment. A Blinded Outcomes Assessor will be masked to study group assignment. Only the study pharmacist, an unblinded study physician, and Data Coordinating Center staff will be unblinded to gel treatment assignment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in six minute walk distance at 6 months</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Distance that the individual can walk on a specified track, within six minutes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Total Lean Body Mass at 6 months</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Total lean body mass measured by dual x-ray absorptiometry (DXA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Appendicular Lean Body Mass at 6 months</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Lean body mass of the arms and legs, measures by dual x-ray absorptiometry (DXA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 1-repetition maximum (1-RM) leg press strength at 6 months</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>1-repetition maximum strength for leg press</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total Modified Physical Performance Test (mPPT) Score at 6 months</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>9 objective physical performance tasks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Short Physical Performance Battery (SPPB) Score at 6 months</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>3 objective physical performance tasks (Chair rise, Progressive Romberg, Walking speed for an 8 ft course)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Older Adult Resources and Services Activities of Daily Living (ADL) Questionnaire (OARS) ADL Total Score at 6 months</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Standardized self-report questions regarding performance of activities of daily living</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Functional Status Questionnaire (FSQ) Total Score at 6 months</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Standardized self-report questions regarding performance of activities of daily living</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hip Rating Questionnaire Total Score at 6 months</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Standardized questions regarding quality of life and function as related to the hip fracture event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health score at 6 months</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Standardized questions regarding quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Bone Mineral Density (BMD) of the non-fractured proximal femur at 6 months</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Bone mineral density measured by dual x-ray absorptiometry (DXA)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">168</enrollment>
  <condition>Hip Fracture</condition>
  <condition>Frailty</condition>
  <condition>Sarcopenia</condition>
  <arm_group>
    <arm_group_label>Exercise + Testosterone (EX + T)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Supervised exercise training 2 times per week and topical testosterone 1% gel (12.5 mg per pump depression) daily, both for six months duration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exercise + Placebo (EX + P)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Supervised exercise training 2 times per week and placebo gel daily, both for six months duration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enhanced Usual Care (EUC)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Home exercise program 3 times per week and monthly health education modules, both for six months duration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone</intervention_name>
    <description>Topical testosterone gel 1%</description>
    <arm_group_label>Exercise + Testosterone (EX + T)</arm_group_label>
    <other_name>T</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo gel</intervention_name>
    <description>Inactive skin gel</description>
    <arm_group_label>Exercise + Placebo (EX + P)</arm_group_label>
    <other_name>P</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Supervised exercise training</intervention_name>
    <description>Multicomponent exercise program focused primarily on progressive resistance exercise training</description>
    <arm_group_label>Exercise + Placebo (EX + P)</arm_group_label>
    <arm_group_label>Exercise + Testosterone (EX + T)</arm_group_label>
    <other_name>EX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Home exercise program</intervention_name>
    <description>Flexibility exercises performed at home 3 times per week and reviewed by study staff once a month.</description>
    <arm_group_label>Enhanced Usual Care (EUC)</arm_group_label>
    <other_name>EUC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Health Education Modules</intervention_name>
    <description>30-40 minute presentations conducted by study staff for participants focused on health concerns unrelated to exercise.</description>
    <arm_group_label>Enhanced Usual Care (EUC)</arm_group_label>
    <other_name>EUC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female 65 years and older.&#xD;
&#xD;
          -  Surgical repair of a non-pathologic fracture of the proximal femur (Including: femoral&#xD;
             neck or intracapsular, intertrochanteric, and subtrochanteric fractures) with a&#xD;
             surgical repair date that is within 24 weeks at randomization. If a revision of such a&#xD;
             fracture is performed due to failure of the repair, that surgery revision date may be&#xD;
             used to calculate the time frame for the screening and randomization dates.&#xD;
&#xD;
          -  Community-dwelling or in assisted living prior to the hip fracture event.&#xD;
&#xD;
          -  Functional impairment at the time of screening, defined as a modified Physical&#xD;
             Performance Score (mPPT) of 12-28.&#xD;
&#xD;
          -  Serum total testosterone level &lt;60 ng/dL.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cognitive impairment or dementia of severity sufficient to interfere with ability to&#xD;
             fully participate in the study or provide one's own informed consent, or a score of 11&#xD;
             or greater on the Short Blessed Test of Orientation, Memory and Concentration.&#xD;
&#xD;
          -  Residence too far from research center (specific distance to be determined by each&#xD;
             site) or planned travel greater than 2 weeks within the next 9 months.&#xD;
&#xD;
          -  Anticipated to be permanently living in a nursing home at the time of randomization.&#xD;
&#xD;
          -  Use of progestin or androgen containing compound within the previous 6 months.&#xD;
&#xD;
          -  Treatment with systemic corticosteroids (daily dose &gt; 5 mg prednisone or equivalent)&#xD;
             for at least 90 days within the previous 12 months.&#xD;
&#xD;
          -  Visual or hearing impairments that interfere with following directions for research&#xD;
             procedures.&#xD;
&#xD;
          -  Active or unstable cardiopulmonary disease (recent myocardial infarction, unstable&#xD;
             angina, class III or IV Congestive Heart Failure) within prior 6 months, which would&#xD;
             limit full participation in the study.&#xD;
&#xD;
          -  Respiratory disease requiring chronic continuous oxygen therapy, or oxygen therapy&#xD;
             during walking or exercise, which would limit full participation in this study.&#xD;
&#xD;
          -  History of idiopathic deep venous thrombosis or pulmonary embolus (i.e., not related&#xD;
             to period or immobilization or surgery), any pulmonary embolus less than 12 weeks&#xD;
             prior to the first screening visit, recurrent or multiple venous thrombi; history of a&#xD;
             hypercoagulable state such as Factor V Leiden thrombophilia.&#xD;
&#xD;
          -  Musculoskeletal or neurological conditions that limit participation in this study,&#xD;
             could be made worse by exercise training, or not expected to improve with exercise.&#xD;
&#xD;
          -  Lower extremity amputation other than toes.&#xD;
&#xD;
          -  Severe lower extremity pain or ulceration that could limit full participation in this&#xD;
             study.&#xD;
&#xD;
          -  History of: a) Breast, ovarian, endometrial or cervical cancer with diagnosis within&#xD;
             the previous 10 years; b) Breast, ovarian, endometrial, or cervical cancer of Stage 2&#xD;
             or higher.&#xD;
&#xD;
          -  History of HIV or active viral hepatitis.&#xD;
&#xD;
          -  End Stage Renal Disease on dialysis or Glomerular Filtration Rate (GFR)&lt;15 ml/min.&#xD;
&#xD;
          -  Allergy to gel components.&#xD;
&#xD;
          -  Recent history of alcohol or substance abuse, or current alcohol intake of ≥ 10&#xD;
             drinks/week.&#xD;
&#xD;
          -  Planned joint surgery during the intervention period.&#xD;
&#xD;
          -  Participation in another research study that in the site investigator's judgement&#xD;
             could interfere or conflict with STEP-HI research assessments or interventions.&#xD;
&#xD;
          -  Current use of aldactone, flutamide or leflunomide.&#xD;
&#xD;
          -  Geriatric Depression Scale (GDS) score ≥ 12 at the screening assessment.&#xD;
&#xD;
          -  Uncontrolled hypertension, defined as a systolic BP &gt; 160 mmHg or diastolic BP &gt; 95&#xD;
             mmHg, on at least two occasions.&#xD;
&#xD;
          -  Elevated liver transaminase or alkaline phosphatase levels ≥ 2.5 times above normal&#xD;
             range.&#xD;
&#xD;
          -  Erythrocytosis defined as hematocrit &gt; 51% (all sites but University of Utah) or ≥ 52%&#xD;
             at University of Colorado - Denver and University of Utah sites.&#xD;
&#xD;
          -  Severe anemia defined as Hgb &lt; 7gm/dL.&#xD;
&#xD;
          -  Uncontrolled diabetes defined as HgbA1C &gt; 10%.&#xD;
&#xD;
          -  Untreated or unstable thyroid disease, with serum Thyroid-stimulating Hormone (TSH)&#xD;
             level ≥ 10 milli-international units per liter (mIU/L) or TSH level ≤ 0.4 mIU/L.&#xD;
             Levels outside of the given range require site physician documentation addressing&#xD;
             treatment or absence of thyroid disease and approval by the Central Coordinating&#xD;
             Center (CCC).&#xD;
&#xD;
          -  Site investigator's judgement that the participant would not be able to complete&#xD;
             research procedures or interventions.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ellen F Binder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kenneth B Schechtman, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jay Magaziner, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland, Baltimore</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ellen F Binder, MD</last_name>
    <phone>314-286-2707</phone>
    <email>ebinder@wustl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kelly M Monroe, MSW</last_name>
    <phone>314-273-1160</phone>
    <email>monroek@wustl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Colorado, Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>University of Connecticut Heath - UConn Health</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather McAbee-Sevick</last_name>
      <phone>806-679-6115</phone>
      <email>mcabeesevick@uchc.edu</email>
    </contact>
    <investigator>
      <last_name>George Kuchel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard Fortinsky, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jenna Bartley, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland School of Medicine/Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>HebrewSenior Life Harvard Medical School</name>
      <address>
        <city>Roslindale</city>
        <state>Massachusetts</state>
        <zip>02131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evelyn O'Neill</last_name>
      <phone>617-971-5347</phone>
      <email>oneill@hsl.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sarah Berry, MD</last_name>
      <phone>617-971-5355</phone>
    </contact_backup>
    <investigator>
      <last_name>Douglas P. Kiel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sarah Berry, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Baldenweck</last_name>
      <phone>314-273-0338</phone>
      <email>meganbaldenweck@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Ellen Binder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Betts</last_name>
      <phone>412-383-6736</phone>
      <email>kmb251@pitt.edu</email>
    </contact>
    <investigator>
      <last_name>Christine McDonough, PT, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch at Galveston (UTMB)</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rae Kretzmer</last_name>
      <phone>409-266-9693</phone>
      <email>rmkretzm@utmb.edu</email>
    </contact>
    <contact_backup>
      <last_name>Eloisa Martinez</last_name>
      <phone>409-266-9643</phone>
      <email>esmartin@utmb.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Elena Volpi, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Slater</last_name>
      <phone>801-213-1539</phone>
      <email>Amanda.Slater@health.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Robin Marcus, PT, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 14, 2016</study_first_submitted>
  <study_first_submitted_qc>October 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2016</study_first_posted>
  <last_update_submitted>July 23, 2021</last_update_submitted>
  <last_update_submitted_qc>July 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>Ellen F. Binder, MD</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcopenia</mesh_term>
    <mesh_term>Frailty</mesh_term>
    <mesh_term>Hip Fractures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

